| Assay Method Information | |
| | Receptor Affinity Assay |
| Description: | It is well-known that drug compounds that have an affinity for the striatal dopamine D2 may give rise to adverse side effects, such as short-term extrapyramidal disorders and tardive dyskinesia. Such adverse effects e.g., have been observed for metoclopramide (CAS No.: 364-62-5), which reduces its utility in particular for the long-term treatment of chronic diseases. The in vitro affinity for the dopamine D2 receptor of Cpd A, and of two prior art compounds metoclopramide and declopramide (CAS No.: 891-60-1) was investigated using an in vitro radioligand binding technique with 125I-spiperone as the radioactive ligand. |
| Affinity data for this assay | |
|---|---|
| If you find an error in this entry please send us an E-mail | |